Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.

doi:10.1111/dom.14267

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.

Diabetes, obesity & metabolism - 1 Mar 2021

Mullally Jamie A, Chung Wendy K, LeDuc Charles A, Reid Tirissa J, Febres Gerardo, Holleran Steven, Ramakrishnan Rajasekhar, Korner Judith

Abstract excerpt

Naltrexone/bupropion (NB) is a US Food and Drug Administration-approved antiobesity medication. Clinical trials have shown variable weight loss, with responders and non-responders. NB is believed to act on central dopaminergic pathways to suppress appetite. The Taq1A polymorphism near DRD2 (rs1800497) is associated with the density of striatal dopamine D2 receptors, with individuals carrying the A allele (AA or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Naltrexone

Share to Pilot Projects

Share to Polymorphism, Single Nucleotide

Share to Protein Serine-Threonine Kinases

Share to Receptors, Dopamine D2

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 33236485
DOI: 10.1111/dom.14267
PMCID: PMC8106923

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.PMID 33236485Read ↗

TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients.Semantic proximity Read ↗

Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report.Semantic proximity Read ↗

Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention.Semantic proximity Read ↗

The Taq IA and Ser311 Cys polymorphisms in the dopamine D2 receptor gene and obesity.Semantic proximity Read ↗

Dopamine for "wanting" and opioids for "liking": a comparison of obese adults with and without binge eating.Semantic proximity Read ↗

Binge eating disorder and the dopamine D2 receptor: genotypes and sub-phenotypes.Semantic proximity Read ↗

Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity ClinicSemantic proximity Read ↗

Assessment of the Association of D2 Dopamine Receptor Gene and Reported Allele Frequencies With Alcohol Use DisordersSemantic proximity Read ↗

D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes.Semantic proximity Read ↗

Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review.Semantic proximity Read ↗

Association of dopamine D2 receptor and leptin receptor genes with clinically severe obesity.Semantic proximity Read ↗

DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophreniaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.